Therapy Areas: Diabetes
ThromboGenics announces plans to change name to 'Oxurion'
27 June 2018 -

ThromboGenics NV (EBR: THR) announced on Wednesday its intention to change its name to Oxurion NV.

The name Oxurion is derived from a combination of 'oxygen' and 'Orion'. Increasing oxygen levels plays a key role in helping to prevent and reverse several of the key underlying factors leading to diabetic eye disease. Oxygen, therefore, references the company's mission to target the onset of these diseases.

Orion was a Greek mythical figure who, after being blinded, had his vision restored by the God of the Sun, Helios. Again, this is a reference to the company's mission to focus on enhancing vision and fighting blindness through its research and drug treatments.

The company has issued a convening notice seeking the approval of its shareholders for the name change at an extraordinary general meeting (EGM), set to take place on Friday 27 July.

Subject to shareholder approval, the name change will come into effect in the week commencing 10 September. The name change will also result in the company's stock ticker symbol changing from 'THR' to 'OXUR'.

Login
Username:

Password: